Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short course Daratumumab in MRD positive multiple myeloma
NCT03490344Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2018
- Primary completion
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in multiple myeloma (MM), sponsored by Memorial Sloan Kettering Cancer Center. Started May 2018; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03490344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03490344.